Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
Hospital Clínic de Barcelona · Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · +24 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,098
total citations
- FWCI
- 45.32
- Percentile
- 100%
- References
- 39
Citations per year
Authors
20- JBJordi BruixCorresponding
Hospital Clínic de Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona
- TTTadatoshi Takayama
Nihon University, Nihon University Itabashi Hospital
- VMVincenzo Mazzaferro
Fondazione IRCCS Istituto Nazionale dei Tumori
- GCGar-Yang Chau
Taipei Veterans General Hospital
- JYJiamei Yang
Second Military Medical University, Eastern Hepatobiliary Surgery Hospital
Topics & keywords
Topics
Keywords
- Medicine
- Sorafenib
- Placebo
- Hepatocellular carcinoma
- Internal medicine
- Surgery
- Clinical endpoint
- Population
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.